Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications. The company’s own clinical programs include gene therapies for inherited retinal diseases and neurodegenerative disorders, while its contract development and manufacturing services support partners working on CAR-T and other cell therapies. By combining process development with large-scale GMP manufacturing, Oxford BioMedica offers end-to-end solutions from preclinical stages through to commercial launch.
Partnerships with leading biopharmaceutical companies underscore Oxford BioMedica’s role as a strategic supplier of viral vectors. The company has collaborated on landmark programmes, including lentiviral-based therapies that have reached regulatory approval in major markets. These alliances leverage Oxford BioMedica’s expertise in vector design, analytical methods and supply chain management to accelerate novel therapies toward patients.
Founded in 1995 as a spin-out from the University of Oxford, the company operates facilities in the United Kingdom and the United States, serving a global clientele. Oxford BioMedica’s leadership team comprises experienced biopharma executives with backgrounds in cell and gene therapy development, manufacturing scale-up and commercial strategy. The organization continues to expand capacity to meet growing demand for gene and cell therapy vectors worldwide.
AI Generated. May Contain Errors.
